Large market reach Position BillionToOne's precision diagnostics and single-count DNA molecule counting capabilities to target mid to large biotechnology and clinical labs seeking scalable, accurate molecular testing with potential expansion into oncology, prenatal, and infectious disease panels.

Liquid biopsy expansion Leverage the launch of Northstar Origin and the expanded Northstar Select gene panel to upsell existing customers on comprehensive liquid biopsy solutions and tissue-of-origin testing, emphasizing broader gene coverage aligned with FDA approvals.

Clinical validation Highlight the large prospective studies and publication in reputable journals to build trust with hospital systems and payer networks, enabling opportunities with academic medical centers and credentialed labs requiring robust real-world evidence.

Strategic partnerships Target collaboration opportunities with CROs, diagnostic developers, and health systems that can integrate BillionToOne's counting platform into multi-gene panels, companion diagnostics, or population screening programs, accelerating adoption.

Investor confidence signals Monitor investor activity and conference participation to identify buyer-side interest from large biotech funds and strategic buyers, using those signals to time outreach to corporate development and procurement teams.